Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04439539 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT04439539 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 54 participants.
The verdict
NCT04439539, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).
Interventions
- DRUG Tenofovir alafenamide
- DRUG JNJ-56136379
- DRUG Tenofovir disoproxil
- DRUG JNJ-73763989
- DRUG PegIFN-alpha-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2024-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04439539
The ClinicalTrials.gov registry entry for NCT04439539 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tenofovir alafenamide is the first listed.
NCT04439539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04439539 about?
NCT04439539 is a clinical study titled "A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection". The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).
What is the current status of trial NCT04439539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2020-09-14. Estimated completion is 2024-02-13.
What interventions are being tested in trial NCT04439539?
The interventions under investigation include: Tenofovir alafenamide (DRUG), JNJ-56136379 (DRUG), Tenofovir disoproxil (DRUG), JNJ-73763989 (DRUG), PegIFN-alpha-2a (DRUG).
Who is sponsoring clinical trial NCT04439539?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.